Brenda Cuellar
Family Medicine · Las Cruces, NMNPI 1811338452
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 482 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,150 and has fallen 99.0% since, to $21 in 2025. Among family medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 482 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boehringer Ingelheim$1K
- AstraZeneca$819
- Amgen$661
- Lilly USA, LLC$645
- GSK$548
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,578100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 90 | $1,416 |
| Boehringer Ingelheim | 49 | $1,113 |
| AstraZeneca | 44 | $819 |
| Amgen | 34 | $661 |
| Lilly USA, LLC | 62 | $645 |
| GSK | 17 | $548 |
| AbbVie(2 entities) | 27 | $464 |
| Merck | 29 | $419 |
| Pfizer | 27 | $382 |
| Sanofi-aventis U.S. LLC | 23 | $350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $332 |
| Abiomed | 2 | $231 |
| Novartis | 10 | $150 |
| Johnson & Johnson | 7 | $118 |
| Mylan Specialty L.p. | 2 | $118 |
| Nalpropion Pharmaceuticals LLC | 6 | $101 |
| Edwards Lifesciences | 1 | $95 |
| Abbott | 3 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Actelion Pharmaceuticals US, Inc. | 1 | $60 |
| Ultragenyx Pharmaceutical Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $52 |
| Astellas Pharma US Inc | 2 | $47 |
| Therapeuticsmd, Inc. | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Bayer | 2 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Organon | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,578 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 18 | $26,181 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,163 |
| LevemirInsulin Detemir | 11 | $3,166 |
| Metformin Hcl | 56 | $541 |
| Atorvastatin Calcium | 35 | $403 |
| Omeprazole | 33 | $390 |
| Levothyroxine Sodium | 39 | $389 |
| Lisinopril | 34 | $287 |
| Tamsulosin Hcl | 25 | $262 |
| Felodipine ErFelodipine | 11 | $249 |
| Famotidine | 20 | $238 |
| Glipizide | 17 | $206 |
| Losartan Potassium | 25 | $199 |
| Simvastatin | 14 | $163 |
| Clonidine Hcl | 20 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $645 | $26,18118 claims |
| Boehringer IngelheimSpiriva Respimat | $1,113 | $6,16311 claims |
| Novo NordiskLevemir | $1,416 | $3,16611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $38939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Las Cruces
- Delliah StamppLas Cruces$21K
- Conchita PazLas Cruces$16K
- Sergio HuertaLas Cruces$11K
- Imelda Toledo-NeelyLas Cruces$7K
- Aaron PfauLas Cruces$4K
- Mai OushyLas Cruces$3K
- Jie LuoLas Cruces$3K
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.